Transcatheter pacing systems are self-contained, leadless, devices that offer the potential benefits of avoiding complications related to pectoral pocket and upper extremity vascular access. These systems in preapproval trials demonstrated excellent safety profile with the incidence of device related cardiac perforation as low as 1.6% with Micra TM (Medtronic, Minneapolis, MN) and 1.3% in Nanostim (Abbott, Abbott Park, IL). In post approval registry of Micra TM TPS the rate of major complications was even lower than in investigational study ranging from 0.63 to 0.77%. Recently, published report found a much higher rates of need for rescue surgery, shock, tamponade, and death among patients implanted with the Micra TM device when compared with transvenous devices. This case reports describes two cases of major right ventricular perforation requiring surgical intervention.